Troy Edward Wilson
Director; Director, President and CEO · 7 filings · Latest: Sep 14, 2026
Atrium Therapeutics, Inc.
Avidity Biosciences, Inc.
Kura Oncology, Inc.
PUMA BIOTECHNOLOGY, INC.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
PBYI | Troy Edward Wilson | Director | Sep 14, 2026 | Sale | $9.10 | 5,000 | $45.5K | 54,750 | |
PBYI | WILSON TROY EDWARD | — | Sep 14, 2026 | Proposed Sale | $9.10 | 5,000 | $45.5K | — | |
KURA | Troy Edward Wilson | Director, President and CEO | Aug 24, 2026 | Purchase | $12.39 | 100,000 | $1.2M | 479,194 | |
KURA | Troy Edward Wilson | Director, President and CEO | Aug 17, 2026 | Purchase | $11.12 | 100,000 | $1.1M | 379,194 | |
PBYI | Troy Edward Wilson | Director | Jun 12, 2026 | Sale | $7.20 | 10,800 | $77.7K | 59,750 | |
PBYI | WILSON TROY EDWARD | — | Jun 12, 2026 | Proposed Sale | $7.26 | 10,800 | $78.4K | — | |
KURA | Troy Edward Wilson | Director, President and CEO | Mar 23, 2026 | Option Exercise | $6.15 | 6,103 | $37.5K | 435,456 | |
KURA | WILSON TROY EDWARD | — | Sep 29, 2025 | Proposed Sale | $9.05 | 36,615 | $331.4K | — | |
RNA | WILSON TROY EDWARD | — | Sep 5, 2025 | Proposed Sale | $50.00 | 95,052 | $4.8M | — | |
RNA | WILSON TROY EDWARD | — | Aug 6, 2025 | Proposed Sale | $45.00 | 95,054 | $4.3M | — | |
PBYI | WILSON TROY EDWARD | — | Jun 13, 2025 | Proposed Sale | $3.40 | 10,800 | $36.7K | — |